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ABSTRACT 
Evidence-based healthcare requires that relevant outcomes for patients are included in clinical 
trials which investigateing treatment effects so thatallowing subsequent systematic reviews 
canto summarize all relevant evidence to guide clinical practice. Currently, no gold standard 
of outcome choice for dermatology trials and reviews exists. We systematically assessed the 
degree of concordance between efficacy outcomes in systematic reviews and their included 
trials in a random sample of 10 Cochrane Skin systematic reviews,  and the containing 220 
dermatology trials included. Reviews did not include 742 (68%) of the 1,086 trial outcomes. 
Of the 60 outcomes the reviews sought, 17 (28%) of these were not reported in any trial 
whilst 12 were assessed in less than 50% of trials. For 11/23 (48%) primary review outcomes 
meta-analysis was impossible, because trial outcomes were absent or unclear. This small 
overlap of review/trial outcomes could suggest that trials are not measuring the outcomes 
perceived to be the most important by patients, clinicians, systematic reviewers and trialists. 
The lack of standardized outcome measures, poor reporting of outcomes in trials and low 
concordance of outcomes between reviews and primary studies could be improved by the 
development and implementation of Core Outcome Sets (COS). These are an agreed 
minimum set of key outcomes, for specified conditions, to be reported in all trials. 
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INTRODUCTION 
In evidence-based healthcare, a key determining factor of the scientific value of clinical trials 
is the choice of outcome. It is of the utmost importance for trials to choose outcomes that are 
considered relevant to patients, clinicians and other healthcare professionals as well as 
decision-makers such as commissioners and policy-makers. Outcome measurement 
instruments must be reliable, valid, and feasible (Boers, 2014, Boers et al., 1998). Trials using 
inappropriate outcomes may overestimate, underestimate or overlook the effect of the 
intervention under investigation (Sinha et al., 2008) and standardization is crucial in order to 
allow cross-trial comparisons in systematic reviews. Similarly, meta-analyses are only 
possible with comparable outcomes. Moreover, using different outcomes across clinical trials 
can hinder clinicians who consider trial data, systematic reviews or meta-analyses in their 
clinical decisions or when formulating clinical practice guidelines. Low or unclear reliability, 
validity, and feasibility of many outcome measurement instruments and lack of 
standardization in outcome assessment in trials have been identified as significant barriers 
towards evidence-based decision-making (Chalmers and Glasziou, 2009). 
 
In the current absence of formal standardization of outcome reporting in clinical trials, for 
almost all dermatological diseases, systematic reviewers need to have an overview of the 
outcomes used in relevant trials before they finally choose review outcomes. Nonetheless, 
through the involvement of clinical and methodological experts and consumers, the choice of 
outcomes in Cochrane reviews generally tend to capture the key benefits and harms of 
treatments. A low degree of overlap between trial and review outcomes would potentially 
indicate that trials were not measuring the outcomes believed by the wider healthcare 
community to be particularly important. It would also raise the possibility of weaknesses in 
systematic review conclusions.   
 
 
 
A preliminary overview of the choice of outcomes in all 69 reviews of the Cochrane Skin 
Group (CSG) published until January 2015 suggested a substantial mismatch between the 
outcomes of interest to the review and those reported in the included clinical trials (Schmitt et 
al., 2016). Only 67% (n=271) of 402 predefined review outcomes were found in at least one 
component trial of the reviews. There are almost no mutually agreed standards for outcome 
selection in dermatological research. Such agreements aim to make trials relevant and 
comparable and the evidence more usable for clinical decision-making. Our preliminary 
overview was based on the database of the Cochrane Collaboration, which provides 
information that can be used to investigate the overlap of review outcomes with trial 
outcomes but not vice versa.  
 
The number of outcomes that trials report but are not included in systematic reviews, and the 
subsequent waste of research effort, is unknown and it was not addressed in our preliminary 
overview. If a sufficient lack of concordance were to exist between trial and review outcomes 
then the development of clinical guidelines could suffer. Consequently, primary researchers 
could lose motivation if significant amounts of their research were arguably wasted by failing 
to become incorporated into clinical guidelines. Funding bodies wishing to see a 
demonstrable impact for their money may likewise wish to ensure that trial outcomes are 
likely to be used by policy makers and guideline developers. 
 
The primary aim of this study was to systematically investigate the overlap between outcomes 
reported in trials and those sought by Cochrane reviews and vice versa. Our secondary aim 
was to conduct a meta-epidemiological study into whether the pooled treatment effect differs 
between trials that are concordant with review primary outcomes versus those that are not. 
 
 
 
RESULTS 
The article selection process is displayed in figure 1. A summary of the Cochrane reviews, 
efficacy primary outcomes and meta-analyses is given in table 1 and the characteristics of the 
included trials are shown in supplement table 1. A total of 20/242 trials (8%) were excluded 
from the study due to the absence of full texts (7), not being published in a language native to 
the study’s researchers (8) (English, German, Italian or Spanish) or containing no relevant 
information (5).  In one review (Bamford et al., 2013) 11 of the trials evaluated were industry 
reports. All other trials were published in scientific journals. In the Cochrane reviews 23 
outcomes were specified as primary (table 1, supplement table 2) and 37 as secondary 
(supplement table 3). Of note is that some texts contained information on more than one trial. 
 
Our assessments of the trials’ Risks of Bias (risk of bias) were given as “high” in 7 out of 10 
reviews and “unclear” in the remaining three reviews. Risks of Bias RoB was noted to be 
particularly high across all trials for the blinding of participants and personnel (supplement 
table 4). It was also “high or unclear” in the allocation of sequence concealment, the blinding 
of trial outcome assessment and other potential threats to validity. 
 
Lack of overlap between trial outcomes and review-sought outcomes 
Figure 2 shows that of the 1086 outcomes identified amongst 220 trials, 742 (68%) were not 
included in the reviews. The median number of outcomes per trial was 4 (range 1 – 34). Of 
the 60 outcomes the reviews sought, 17 (28%) of these were not reported in any trial.  
 
Missing outcomes 
 
 
 
Supplement table 2 shows that 3/23 (13%) outcomes that reviews sought as primary were 
missing in every relevant trial. These were “participant-rated global improvement” (Chen et 
al. (2013) - Psoriasis), “improvement in sleep” (Ersser et al. (2014) - Atopic eczema) and 
“participant dis/satisfaction” (Kwok et al. (2012) - Warts). The mean presence in the trials of 
any specified review-sought primary outcome, irrespective of whether reported by trials as 
primary or secondary, was 45% (95% CI 32 to 59%).  
 
14/37 (38%) secondary review outcomes were missing completely (supplement table 3). The 
mean presence in the trials of any specified review-sought secondary outcome, irrespective of 
whether reported by trials as primary or secondary, was 23% (95% CI 14 to 32%). The review 
with the most secondary trial outcomes (80%) was for pemphigus (Martin et al., 2009). The 
review with the least (21%) was for psoriasis (Chen et al., 2013). 
 
Lack of concordance  
Of the total 1086 trial outcomes that this study identified, those that the Cochrane authors 
defined as primary were seen 215 times. 31/215 (14%) of these were reported by the trials as 
primary. The outcomes that the reviews defined as secondary were present 129 times in the 
trials but only reported as secondary in 16 trials (12%). 
 
Of the 23 outcomes sought as primary by the reviews 11 (48%) were not reported as such by 
the trials. 30/37 (81%) outcomes sought as secondary by the reviews were not reported as 
such by the trials. 
 
 
 
The degree of concordance between reviews and trials agreeing on which outcomes should be 
primary or secondary is displayed in figure 3. The planned meta-epidemiologic analyses for 
the secondary objective of the study were not possible due to this lack of data. 
 
The primary review outcome seen the most as a primary trial outcome ("Reduction in disease 
severity as measured [objectively] by a trained assessor") was present in 33% of trials 
assessed in the review by Ersser et al. (2014) (atopic eczema). The mean proportion of 
concordance between trial outcomes being sought as primary by reviews and being reported 
as primary by trials was 7% (95% CI 3 to 12%).   
 
The secondary review outcome seen the most ("Response rates (partial and complete)") was 
reported as ‘secondary’ in 8% of trials assessed in the review by Sasse et al. (2007) 
(metastatic malignant melanoma). The mean concordance between secondary review 
outcomes and secondary trial outcomes was 2% (95% CI 0 to 4%).   
 
Loss of potential data for systematic reviews 
The Cochrane authors defined the outcomes they wished to consider in their reviews. In then 
selecting the trials to assess they implicitly established the maximum number of times they 
could have seen these outcomes. This potential figure can be derived as “number of outcomes 
sought by the review” multiplied by “number of trials included in the review”.  Figure 4 
illustrates how much of this data was indeed seen by the Cochrane reviews. Irrespective of 
whether trials reported outcomes as primary or secondary, the mean value of potential 
realized was only 35% (95% CI 27 to 43%). For trial outcomes specified as primary or 
secondary in concordance with the reviews' requirements the mean value of potential realized 
was 5% (95% CI 2 to 7%)).  
 
 
 
The Cochrane reviewers frequently commented on the difficulties they faced due to absent or 
significantly heterogeneous trial outcomes and due to insufficient focus on patient-centered or 
quality-of-life matters (supplement table 5). In every single Cochrane review included in this 
study trial inconsistencies, lack of standardization and insufficient reporting were identified as 
major impediments for summarizing research evidence. 
 
Outcome domains 
An example of an outcome domain is “Quality of Life (QoL)” which would contain any 
outcome or measure which assessed QoL, irrespective of the actual instrument used. The trial 
outcomes considered by the reviews fell into several domains and these are shown in 
supplement table 6. This displays that despite a lack of concordance for many specific 
outcomes there was better agreement at the outcome domain level. For example, 27 trials into 
atopic eczema were assessed in Bamford et al. (2013); “Global disease severity” and “single 
symptom” were domains containing the primary outcomes defined by the Cochrane review 
and domains containing outcomes reported in 22 (85%) and 20 (77%) of trials respectively. 
 
DISCUSSION 
In evaluating the efficacy of interventions, evidence from randomized clinical trials represents 
scientifically rigorous evidence from a primary study design. Typically, clinical trials are 
designed to test the effect of exposure to a defined intervention versus control on specific 
primary efficacy or safety outcome(s). The trial design, statistical analysis employed and 
choice of sample size is focused on investigating the effect of an intervention on a primary 
outcome. The results of a trial can only be interpreted as confirmatory for this primary 
outcome (Hanson, 2008). Effects of the intervention on secondary trial outcomes have to be 
 
 
interpreted as exploratory or hypothesis generating. The high level of evidence produced by 
clinical trials therefore applies predominantly to the primary outcome(s). From a 
methodological perspective, pooled evidence from confirmatory trials (i.e. trials with the 
same primary outcome as the review) may allow more valid conclusions regarding the 
efficacy of interventions than pooled evidence from exploratory trials (i.e. trials with a 
different primary outcome as the review). Meta-epidemiologic evidence on this critical 
research question is missing. 
 
Main findings 
Our study set out to analyze the degree of overlap between trial outcomes and those sought by 
reviews for a broad spectrum of dermatological conditions including psoriasis, melanoma, 
atopic eczema, pemphigus, seborrheic dermatitis, and cutaneous warts.  
 
We identified a low degree of agreement between trial and review outcomes. This could 
indicate a vulnerability of systematic review conclusions. As the choice of outcomes in 
Cochrane reviews is designed to capture the key benefits and harms of treatments, this small 
overlap of review/trial outcomes could also suggest that many trials are not measuring the 
outcomes perceived to be the most important by patients, clinicians and other allied healthcare 
professionals. 
 
Missing outcomes and loss of potential data for reviews  
Our results demonstrate that a significant number of outcomes sought by reviews are missing 
in trials. This represents the first time such a substantial absence of data has been specifically 
identified in the dermatological field. The systematic review of any topic is impossible when 
 
 
the required outcomes are not present in the published trials. Indeed due to this reason, and 
the heterogeneity of those trial outcomes that were actually reported, no meta-analysis was 
possible for 11/23 (48%) of the primary review outcomes. This represents a sizeable loss of 
possible conclusions to a review and to the potential subsequent evidence-based guidelines. 
90% of reviews in our study were missing more than 50% of outcome data they would have 
had if every trial had reported every outcome the reviews wanted to assess. This finding is 
worse than that seen in a meta-analysis of general systematic reviews (Kirkham et al., 2010, 
Kirkham et al., 2013). In this, only 25% of reviews were missing more than 50% of potential 
data. 
 
Limited usability of research effort 
68% of all trial outcomes not being included in the reviews reflects how much research effort 
went no further than the original trial and leads to the question of how trialists decide which 
outcomes to use in their study. 
 
Lack of concordance 
The significant lack of concordance between reviews looking to assess specific outcomes as 
primary or secondary and trials investigating them as such had a substantial impact on the 
susbsequent reviews and meta-analyses. Review authors directly commented on this.  
 
Mutual agreement of core outcomes, rather than being based solely on a review author’s 
opinion, would particularly facilitate a relevancy informed by multiple viewpoints. This, in 
turn, may support better uptake and implementation by researchers of the concept. 
 
Risk of Bias  
 
 
Outcome reporting bias (ORB), the selection for publication of a subset of the originally 
recorded outcome variable (Williamson and Gamble, 2005), was more prevalent in our study 
than in a meta-analysis of general systematic reviews. This found 34% of assessed reviews 
contained at least one trial with high suspicion of ORB (Kirkham et al. (2010), recommended 
by Cochrane for systematic reviewers). The corresponding figure for our study was 70%. 
 
Outcome domains 
There was broader concordance between the trials and reviews with regards outcome domains 
than there was concordance for defined specific outcomes. This suggests that trialists and 
reviewers are, in general, considering similar areas of particular diseases rather than 
completely different aspects. As such, this implies that better concordance of specific 
outcomes is eminently achievable. 
 
Limitations 
We decided to analyse Cochrane reviews, because the Cochrane Handbook makes patient 
representation and involvement in review teams mandatory so that the choice of outcomes 
chosen in these reviews can be assumed to reflect the patient perspective. The 10 systematic 
reviews that we assessed represented only 15% of the 69 Cochrane Skin systematic reviews 
published during the time-period of sampling for our study. Since then 37 more have been 
published.  
 
Our allocation of trial outcomes to systematic review outcome domains was performed 
iteratively. A uniform taxonomy was missing and allocation had the potential to be piecemeal. 
 
 
 
Whether results apply to non-Cochrane reviews is unclear. For Cochrane, authors are 
encouraged to decide which primary review outcomes should be measured before looking at 
the data and to publish their intentions in a protocol. Non-Cochrane reviews may not do this 
and be more data driven, basing their choice on what is available. This could lead to better 
concordance but not necessarily better evidenced reviews. Evaluating the discordance in 
outcomes is particularly relevant for evidence-based practice.  
 
Outcome identification in the primary trials was sometimes challenging, especially when the 
methods sections were not well developed. This difficulty may have led to undereporting of 
outcomes, if they were not clearly designated as such. 
 
Implication for further research and perspective 
Our study found a low degree of overlap between trial and review outcomes. This could 
facilitate weaknesses in systematic review conclusions due to insufficient data. Core 
Outcomes Sets (COS) may be a solution here and they are increasingly being developed to 
standardize outcomes across trials and to allow cross-trial comparisons. In dermatology, the 
harmonizing outcome measures in eczema (HOME) initiative pioneered COS development 
(Schmitt et al., 2015). Other groups have started COS development in other fields of 
dermatology, but none of these groups has yet implemented their COS. 
 
We suggest that the main effort of future research in this field should be not only the 
development but also the implementation of COS in dermatology. The Cochrane Skin – Core 
Outcome Set Initiative (CS-COUSIN) has recently been established to improve and 
standardize outcome measurement in clinical trials and to make trial evidence more usable 
 
 
(Kottner et al., 2018, Schmitt et al., 2016). Further aims are to develop clinically relevant and 
patient-centered sets of dermatological trial outcomes and improve the quality and 
interpretability of systematic reviews. Ultimately, the objective is to facilitate dermatological 
research delivering a tangible clinical impact for patients through evidence-based healthcare.  
The implementation of COS requires high acceptability of all stakeholder groups including 
key clinicians, researchers, patient representatives, but also regulators (FDA, EMA), 
pharmaceutical industry, and journal editors. Journal editors have been for example involved 
in the first HOME Delphi study published in the JID (Schmitt et al., 2011). Ideally, journal 
editors should encourage the application of existing COS in their guidelines for authors. 
Funders of clinical trials already do so in the UK and in Germany. 
 
The CS-COUSIN initiative will primarily achieve this by supporting research groups as they 
develop a COS. Specifically, CS-COUSIN provides expert and ongoing peer-based 
methodological advice (e.g., regarding outcome measurement (Grinich et al., 2018)), a 
development pathway and administrative support for the lifespan of the COS projects. Its 
structured and experienced approach can also help reduce bias risk. Core outcomes and, 
crucially, measurement instruments are currently in progress for 16 disease areas (including 
acne, chronic spontaneous urticaria, chronic wounds, atopic & hand eczema, melanoma, 
rosacea, hidradenitis suppurativa, nail psoriasis and basal cell carcinomas). CS-COUSIN can 
further help to reduce the risk of bias which in our study was also worse than in others. 
Specifically, the impact of selective reporting of outcomes seen in Outcome Reporting Bias 
could be reduced (Williamson et al., 2012). This has been shown to hamper systematic 
reviews significantly (Kirkham et al., 2010).  
 
 
 
The CS-COUSIN initiative is constantly open to new members looking to develop a COS, 
join a current project group, use a specific COS, receive methodological advice or join as a 
patient-representative. To discover more, and how we could help you make COS in 
dermatology a reality, please scan the website and twitter QR codes in figure 5 or visit our 
website (www.cs-cousin.org). 
 
MATERIALS AND METHODS 
This study was an investigation of a random sample of systematic Cochrane Skin Group 
Reviews and the component trials. 
  
Protocol and registration 
A review protocol was developed and published at PROSPERO in September 2015 
(CRD42015025005). 
 
Data source and data collection 
A random sample of 10 systematic reviews of the Cochrane Skin Group published until 
January 2015 and their component trials. A random sample was drawn, using the statistical 
software “R”, from all 69 CSG reviews in dermatological diseases published until January 
2015. The 10 reviews included 242 primary studies (range: 7 to 85 studies). Only trials 
written in English, German, Italian or Spanish were included. 
 
Data extraction 
Where possible, Cochrane provided clinical trial data from the ARCHIE database 
(https://archie.cochrane.org/). This consisted of data originally extracted by the systematic 
 
 
review team from the trials they included during their reviewing process. Independent 
reviewers extracted data at both trial and systematic review level and data were double 
extracted. 
 
Review global-data extraction 
The following information was extracted from each review; whether a meta-analysis was 
performed, the reasons why no meta-analysis was performed as applicable, specifically 
“heterogeneity” in outcome measurement across trials as the reason, the number of trials 
included in the meta-analysis of the primary efficacy outcome of the systematic review and 
the number of trials not included in the meta-analysis of the primary efficacy outcome (total 
and due to no assessment of primary review outcome in underlying trials). 
 
Trial global-data extraction  
For each trial we extracted published data on general characteristics (year, geographical bias 
(assessed by the Cochrane risk of bias instrument), outcomes (i.e. primary, secondary, not 
specified), and results (with respect to the primary outcome the number of patients 
randomized and the number of events per group). 
 
If outcomes were not explicitly classified as primary or secondary, we assumed an outcome 
was a primary outcome when sample size calculations were based on this outcome. 
Otherwise, the outcome was classified as “not specified”. If there was a reference to a study 
protocol in the trial, we also obtained this to extract the relevant data. 
 
Outcome extraction 
 
 
For each trial and review outcome we extracted the outcome domain(s), measurement 
instrument or outcome definition, number of participants and events in both the intervention 
and the control group (for reviews only applicable if meta-analysis has been conducted) and 
whether the outcome was the primary or secondary outcome or if there was no information in 
this respect. 
 
Protocol deviation 
We had planned to compare pooled outcomes from meta-analysis of all trials to the pooled 
effects of (1) component trials with the primary review outcome used as primary, (2) 
secondary, or (3) unspecified outcome with the 2-step meta-epidemiologic approach (Savovic 
et al., 2012). The planned meta-epidemiologic analyses, however, for the secondary objective 
of the study became unfeasible due to a lack of data. 
 
Data collection process 
Outcomes were extracted in duplicate independently from the original publications by two 
reviewers using a standardized electronic template in MS Access. Then both data sets were 
compared and all areas of disagreements were resolved. 
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Tables 
Table 1: Summary of included Cochrane reviews, primary efficacy outcomes, and realization meta-analyses  
Cochrane Review 
 
(Number of trials 
included in this study / 
number in review) 
 
Mention of 
primary outcome 
in abstract or 
plain language 
summary 
Primary Review Outcome(s) If sub-group or meta-analysis was conducted n of 
trials included / not included  
Reason for non-
inclusion of trials in 
meta-analysis 
If no meta-analysis was 
conducted  
 
Reason 
Bamford et al. (2013) 
(atopic eczema) 
 
(26/27) 
In plain language 
summary 
Primary efficacy outcome I: Global degree of 
improvement in symptoms and signs as rated by 
participant or medical doctor. 
Participant: 12/27 reported primary efficacy outcome, 
7/12 included in meta- analysis. 2 subgroup analyses (1 
included 2 trials, 1 included 5 trials).   
Clinician: 19/27 reported primary efficacy outcome 8/19 
included in meta-analysis. 2 subgroup analyses (1 
included 3 trials, 1 included 5 trials) 
 
 Trials reported this outcome, but 
in different ways. 
  Primary efficacy outcome II: Improvement in quality of 
life. 
No meta-analysis  Only 2 trials reported the 
primary outcome but these could 
not be pooled as they compared 
different interventions 
Bath-Hextall et al. 
(2012) 
(atopic eczema) 
 
(10/11) 
In plain language 
summary  
Primary efficacy outcome I: Degree of long-term (over 
six months) control, such as reduction in number of ﬂares 
or reduced need for other treatments.  
No meta-analysis  For 9/10 trials no data was 
available for the primary 
outcomes  
  Primary efficacy outcome II: Short-term (within six 
weeks). Changes in participant-rated or parent-rated 
symptoms of atopic eczema, such as pruritus (itching) or 
sleep loss. 
   
Chen et al. (2013) 
(psoriasis) 
 
(13/13) 
In abstract 
 
Primary efficacy outcome I:  Participant-rated global 
improvement. 
No meta-analysis 
 
  None of the 13 included trials 
addressed this primary outcome. 
  Primary efficacy outcome II: Percentage of participants 
reaching Psoriasis Area and Severity Index (PASI) 75.  
No meta-analysis 
 
 Only 2/13 trials with different 
interventions addressed this 
primary outcome. 
   Primary efficacy outcome III: Clearance rate, defined as 
no lesions of psoriasis or minimal residual activity 
(MRA) 
 
10 from 13 studies assessed this primary outcome; 
4 studies included in meta-analysis: 2 meta-analysis with 
each 2 studies each subgroup 1: 2/1  
subgroup 2: 2/0 
none or only one study 
per intervention, once 
because of heterogeneity 
between the studies 
 
Chi et al. (2011) 
(lichen sclerosus 
(genital) 
 
(7/7) 
 No Primary efficacy outcome I: Participant-rated 
improvement or remission of symptoms (in terms of 
quality of life, pain, itching, and less pain with 
intercourse). 
6 of 7 studies assessed the outcome 
2 studies included in 1 meta-analysis 
 
1 study did not evaluate 
this outcome.  
 
   Primary efficacy outcome II: Investigator-rated global 
degree of improvement (in terms 
7 of 7 studies assessed the outcome 
no meta-analysis 
  
 
 
of pallor, purpura, hyperkeratosis, ulceration, erosion, 
erythema,sclerosis, and scarring). 
NB: Paper reports in text that “All seven included studies 
reported investigator-rated improvement of gross 
appearance” however, again, variable language used in 
meta analysis for this outcome.  
Eekhof et al. (2012) 
(ingrowing toenails) 
 
(21/24) 
 In abstract and 
plain language 
summary 
Primary efficacy outcome I: Relief of symptoms 
 
no meta-analysis 
 
  
   Primary efficacy outcome II: Recurrence 
 
 
 
Primary efficacy outcome III: Regrowth (including 
nail spicules/nail spikes) 
16 from 24 studies assessed primary outcome recurrence; 
1 meta-analyses 
subgroup 1: 2/1  
 
no meta-analysis 
 
  
Ersser et al. (2014) 
(atopic eczema) 
 
(9/10) 
 In abstract 
 
Primary efficacy outcome I:  participant-rated global 
assessment 
No meta-analysis 
 
 None of the 9 included studies 
addressed this primary outcome. 
 
   Primary efficacy outcome II: reduction in disease 
severity, determined by an assessor using an objective 
measure  
No meta-analysis 
8 / 9 studies assessed severity (6x SCORAD) 
 1. methodological weaknesses in 
the selected studies; 
2. heterogeneity of the outcome 
measures; and 
3. the heterogeneous nature of 
the interventions. 
   Primary efficacy outcome III: improvement in sleep No meta-analysis 
 
 None of the 9 included studies 
addressed this primary outcome 
   Primary efficacy outcome IV: improvement in quality of 
life (or reduction in distress of the child and parent) 
No meta-analysis 
7 from 9 studies assessed QoL 
 
 1. methodological weaknesses in 
the selected studies; 
2. heterogeneity of the outcome 
measures; and 
3. the heterogeneous nature of the 
interventions. 
Kastarinen et al. (2014) 
(seborrheic dermatitis 
(face and scalp) 
 
(35/36) 
 
In abstract 
 
Primary efficacy outcome I: Total clearance (total 
resolution of symptoms), evaluated by an outcome 
assessor [expressed as a % of people treated].  
27 /36 trials assessed the outcome total clearance 
 
15 trials included in 4 meta analyses 
 
 
 
1 study excluded as 
mode of application was 
different from all other 
trials. 
 
1 study excluded as 
clearance defined as 
≥75% which was less 
than in other included 
trials. 
 
  Primary efficacy outcome II: Disease severity scores for 
scaling, pruritus, or erythema at the end of treatment as 
(evaluated by participant self-report, outcome assessor, 
or both). 
28/ 36 trials assessed one of the outcome (scaling, 
pruritus or erythema) 
 
 7 trials included in 3 meta analyses  
 
  
Kwok et al. (2012) 
(common warts,  
No [Efficacy 
mentioned, but no 
Primary efficacy outcome I: Clinical cure (defined as 
complete disappearance of elevated/warty skin) at end of 
treatment period. 
37/85 assessed this primary outcome. 
Meta-analysis:  
The heterogeneity of the 
trials made it difficult to 
 
 
 
cutaneous warts (non-
genital)) 
 
(70/85) 
further details 
given] 
 35 included in meta-analysis: 10 meta-analysis plus 
subgroup-analysis with meta-analysis 
perform statistical 
pooling of the data. 
 
  Primary efficacy outcome II + III: Participant 
satisfaction/dissatisfaction / Quality of Life. 
No meta-analysis 
 
 
  
Martin et al. (2009) 
(pemphigus vulgaris 
and pemphigus 
foliaceus) 
 
(10/11) 
No Primary efficacy outcome I: The proportion of 
participants achieving remission 
(defined as the absence of lesions or the presence of 
transient new lesions that heal within one week, while 
the personis receiving minimal therapy). 
 
 
3 /11 trials evaluated the specified outcome measure 
 
2 trials included in meta analysis (but with the data from 
only one study, because the other is not estimable) 
  
Sasse et al. (2007) 
(metastatic 
malignant melanoma) 
 
(18/18) 
No Primary efficacy outcome I: Overall survival [number of 
participants alive at end of trial]. 
8/18 trials evaluated the outcome overall survival, all 8 
trials were included in a meta-analysis  
  
 
